Integral Health Asset Management LLC Purchases 50,000 Shares of STAAR Surgical (NASDAQ:STAA)

Integral Health Asset Management LLC increased its position in STAAR Surgical (NASDAQ:STAA) by 100.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 100,000 shares of the medical instruments supplier’s stock after buying an additional 50,000 shares during the quarter. Integral Health Asset Management LLC owned 0.20% of STAAR Surgical worth $2,429,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of STAA. KLP Kapitalforvaltning AS bought a new stake in STAAR Surgical in the fourth quarter valued at approximately $180,000. Bridgefront Capital LLC lifted its position in STAAR Surgical by 27.2% in the fourth quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock valued at $262,000 after purchasing an additional 2,306 shares during the last quarter. Quantbot Technologies LP bought a new stake in STAAR Surgical in the fourth quarter valued at approximately $278,000. Y Intercept Hong Kong Ltd bought a new stake in STAAR Surgical in the fourth quarter valued at approximately $292,000. Finally, Counterpoint Mutual Funds LLC bought a new stake in STAAR Surgical in the fourth quarter valued at approximately $298,000. Institutional investors own 96.70% of the company’s stock.

STAAR Surgical Price Performance

NASDAQ STAA opened at $19.36 on Monday. The stock has a market capitalization of $958.82 million, a PE ratio of -47.22 and a beta of 0.65. The business has a 50 day simple moving average of $17.57 and a two-hundred day simple moving average of $21.86. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $49.86.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. BTIG Research downgraded STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday, February 12th. Mizuho downgraded STAAR Surgical from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $45.00 to $17.00 in a report on Wednesday, February 12th. Canaccord Genuity Group upped their target price on STAAR Surgical from $17.00 to $20.00 and gave the company a “hold” rating in a report on Thursday. Jefferies Financial Group downgraded STAAR Surgical from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. Finally, Wells Fargo & Company assumed coverage on STAAR Surgical in a report on Monday, April 21st. They set an “equal weight” rating and a $17.00 target price for the company. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $24.63.

Insider Transactions at STAAR Surgical

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 259,616 shares of the company’s stock in a transaction that occurred on Wednesday, February 12th. The stock was bought at an average price of $14.96 per share, for a total transaction of $3,883,855.36. Following the acquisition, the insider now directly owns 11,137,623 shares in the company, valued at $166,618,840.08. The trade was a 2.39% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders purchased 1,742,581 shares of company stock worth $28,407,543. 1.00% of the stock is currently owned by company insiders.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.